Member Directory

Main activities are: fundraising for early stage life science companies, helping companies become investment ready; advice on obtaining R&D grants; interim and financial management for early stage companies; and contributing to board decisions as non-executive director. Experience includes raising equity for eight life science companies and obtaining R&D grants for 16 others. Also 12 years managing small companies and a number of non-executive director posts.

Bicycle has developed a proprietary bicyclic peptide technology that enables the discovery of a new class of drug candidates with antibody-like selectivity and specificity. The company is well financed by a group of top-tier VCs and is applying the technology to drug discovery projects in several therapeutic areas. The company also plans to also enter selected research collaborations to make the platform available to pharma partners.

Bidwells is the leading property consultancy in the Oxford-Cambridge Arc, advising on over half of all science and technology space in the region. We manage over £5.2bn in property assets for national and international investors, and serve as a gateway to highly attractive markets for science and technology corporations and investors. We help businesses to find or develop new office and laboratory space, project manage fit-outs and refurbishments, and we provide building and planning consultancy, relocation and acquisition advice, and lease consultancy.

Biocair is a global GDP logistics specialist with over 35 years of experience in the pharmaceutical, biotechnology and life sciences sectors.
The company has built up a unique, client-centric approach by employing scientists in front-line logistics positions and assembling a team of best-in-class industry experts in quality, cold chain and regulatory compliance. Biocair focuses on providing the most comprehensive time-sensitive and temperature-controlled logistics services available whilst delivering flexible, tailored, cost-effective solutions to all clients.
The Biocair network operates 24/7 in over 160 countries across Europe, Africa, Asia and the Americas.
Watch our member showcase video here https://bit.ly/3K5dxBO

Research and Development in DNA Manipulation

Biofidelity’s mission is to improve and extend cancer patients’ lives by enabling better targeting of therapies, early detection of treatment resistance, and routine monitoring of treatment response. Our unique technology is designed to allow rapid, broad adoption of our assays in testing labs around the world, enabling a step change in patient care.

The Greater Munich Area is the location of a longstanding, unique network of a strong Life Science industry, scientific institutions and clinics – a network coordinated by BioM Biotech Cluster Development GmbH (BioM). BioM also manages the Bavarian Biotech Cluster of all life science regions in Bavaria. Altogether, 320 life science companies are located in the Greater Munich Area, in Regensburg and Würzburg.. . BioM is a publicly funded service and consulting company with the aim to promote the development of the Munich Biotech Cluster as an internationally renowned centre of excellence in the field of innovative biotechnology and to link its work closely with the other Bavarian biotech regions. BioM supports local biotech start-up companies with a wide variety of services and training tools. Through the network of all important stakeholders in the region, BioM assists Bavarian-based companies in finding the right contacts and partners, also with regards to international markets.

Founded in 2004, BioMed Realty Trust, Inc. (NYSE: BMR; www.biomedrealty.com) delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities in the life science industry. Currently, the company has over $5 billion invested in the state-of-the-art research facilities representing more than 13 million square feet across the United States and the United Kingdom.

BioMedica is your CDMO partner for in-vitro diagnostic and biopharmaceutical product development. Expanding on our core competencies in thrombosis and haemostasis, we combine our operational expertise in formulation, blending, dispensing, lyophilization with over twenty years of experience in submitting for and obtaining regulatory approvals to collaborate internationally with technology development companies and healthcare stakeholders to develop and manufacture customized reagents and diagnostic solutions. Our focus is on providing custom, affordable diagnostic solutions in the global, human and animal health arenas. Working hard to lower costs and reduce and mitigate risks to all stakeholders, BioMedica develops the tools needed for research, education and In-Vitro Diagnostics. With products and technologies in over 70 countries, BioMedica brings innovation, quality, and affordable diagnostic solutions to an ever-growing group of international partners focused on helping to improve patient outcomes.
Helping people live better lives – it’s not only our vision, it’s what we do.

BioMedica Diagnostics has a very competent team to assist with Development, Quality Systems, as well as Manufacturing requirements of your projects within the Life Science sector within our ISO 13485:2016 - MDSAP accredited facility.

BioNJ, The Gateway to Health, is a powerful network of 400 Member Investors representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait, BioNJ is committed to the growth and prosperity of New Jersey’s life sciences ecosystem to help accelerate the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society. As the industry’s voice in New Jersey, we fulfill our Mission to help our Members help Patients by driving capital formation and fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.

Pages